Yes, osteoarthritis causes inflammation. For decades, osteoarthritis (OA) was described as a “wear and tear” condition, implying that joints simply ground down with age. That view has been replaced. Scientists now recognize OA as an active disease process where inflammation plays a central role in both symptoms and cartilage destruction. The inflammation in OA is typically lower-grade than in rheumatoid arthritis, but it is real, measurable, and present from the earliest stages of the disease.
Why the “Wear and Tear” Label Was Wrong
The old framing of osteoarthritis as passive deterioration led to decades of limited research and a fatalistic approach to treatment. But biopsies of joint tissue tell a different story. Even in early OA, before X-rays show any damage, the synovial membrane (the tissue lining the inside of the joint) already shows signs of active inflammation: thickening, increased blood vessel growth, and infiltration by immune cells like macrophages, T cells, and B cells.
These aren’t signs of a joint quietly wearing out. They’re signs of a joint under immune-driven attack. Research in mouse models has shown that macrophage activation in the synovial lining is essential for cartilage damage to occur, meaning inflammation isn’t just a side effect of OA. It’s a driver of it.
What Happens Inside an Inflamed OA Joint
The inflammatory process in osteoarthritis centers on the synovial membrane. In a healthy joint, this membrane produces fluid that lubricates and nourishes cartilage. In OA, the membrane becomes inflamed (a condition called synovitis), and the changes are visible under a microscope: the lining layer thickens, new blood vessels proliferate, and waves of immune cells move in.
These immune cells, along with the cartilage cells themselves, begin releasing inflammatory signaling molecules. The most important ones drive cartilage breakdown by triggering the production of enzymes that dissolve the structural proteins holding cartilage together. One key signal ramps up enzymes that destroy collagen fibers, the scaffolding of cartilage. Another triggers enzymes that break apart aggrecan, the molecule that gives cartilage its ability to absorb shock. The result is cartilage that progressively loses both its structure and its resilience.
What makes this especially damaging is that these inflammatory signals don’t just destroy cartilage directly. They also suppress the production of new cartilage building blocks, so the joint loses its ability to repair itself at the same time the damage accelerates. The inflamed synovial membrane releases these molecules into the joint fluid, where they diffuse into cartilage and perpetuate the cycle.
How OA Inflammation Feels Different From Rheumatoid Arthritis
Both OA and rheumatoid arthritis (RA) involve synovitis, cartilage loss, and bony growths around joints. But the scale and pattern of inflammation differ. RA is a systemic autoimmune disease where the immune system aggressively attacks joint tissue throughout the body, often causing pronounced redness, heat, and swelling in multiple joints simultaneously. Blood markers of inflammation tend to be significantly elevated.
OA inflammation is more localized and lower in intensity. Many people with OA do experience redness, swelling, warmth, and pain in affected joints, and MRI scans frequently detect joint fluid buildup and synovial thickening even before patients report significant symptoms. But the inflammatory markers in blood tests are often only mildly elevated. Researchers have used a CRP (C-reactive protein) threshold of 3 micrograms per milliliter to distinguish higher-inflammation OA from lower-inflammation OA, which is well below the levels typically seen in RA flares.
This subtlety is part of why OA inflammation went unrecognized for so long. It’s real, but it’s quieter than the dramatic inflammation of autoimmune arthritis.
Obesity and Metabolic Syndrome Fuel Joint Inflammation
Excess body weight contributes to OA in two ways, and only one of them is mechanical stress on joints. The second, increasingly recognized pathway is metabolic inflammation. Fat tissue, particularly around the abdomen, functions as an active organ that releases inflammatory signaling molecules called adipokines into the bloodstream. These molecules create a state of chronic, low-grade inflammation throughout the body.
Inside joints, this systemic inflammation shifts the behavior of macrophages, the immune cells that act as the joint’s maintenance crew. Under normal conditions, macrophages lean toward a repair-oriented mode. Obesity and metabolic syndrome push them toward a pro-inflammatory mode that accelerates cartilage erosion and synovial inflammation. This helps explain why OA affects not just weight-bearing joints like knees and hips, but also hand joints in people with obesity, where mechanical load isn’t a factor. Insulin resistance and abnormal cholesterol levels compound the problem, altering the joint’s internal environment in ways that favor ongoing damage.
The inflammatory and metabolic pathways also amplify each other. Inflammatory molecules from damaged cartilage trigger further metabolic disruption, while metabolic dysfunction keeps feeding the inflammatory fire. This self-reinforcing loop is one reason OA tends to progress rather than stabilize.
How Inflammation Shapes OA Treatment
Recognizing inflammation as a core feature of OA has opened new treatment directions. NSAIDs (like ibuprofen and naproxen) have always been a mainstay for OA pain, and their effectiveness makes more sense in light of the inflammatory component. But researchers are now testing whether drugs originally designed for inflammatory arthritis could work in OA as well.
Medications that block specific inflammatory signals are under active investigation. Drugs targeting the TNF-alpha pathway, widely used in rheumatoid arthritis, have been tested in OA patients because this same molecule is produced by synovial cells and cartilage cells in osteoarthritic joints and is linked to OA pain. Similarly, drugs that block interleukin-1, another key inflammatory signal in OA cartilage destruction, are being studied. One newer approach uses a single molecule that blocks two forms of interleukin-1 simultaneously, which showed better results for pain and cartilage protection in animal models than blocking either form alone.
Methotrexate, a cornerstone drug for rheumatoid arthritis, is also being evaluated for OA patients who have measurable synovitis. Early evidence suggests it can relieve joint symptoms, with a potentially stronger effect in patients whose inflammation is confirmed on imaging. Ongoing clinical trials are working to confirm this.
A consistent theme in this research is that anti-inflammatory treatments tend to work better in patients who have a clearly inflammatory subtype of OA, identifiable through MRI-detected synovitis or joint effusion. Not every OA patient has the same degree of inflammation, which may explain why some people respond well to anti-inflammatory approaches while others don’t. This has led researchers to argue for identifying inflammatory OA as a distinct subtype that may benefit from more targeted treatment.